Avalyn Pharma Prices 16.67M Shares at $18.00
Avalyn Pharma priced 16.67M shares at $18.00. The deal priced at the top end of its $16.00-$18.00 target range. Morgan Stanley, Jefferies, Evercore ISI and Guggenheim are acting as joint book running managers for the offering. Avalyn's AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis.
